Table 1.
Baseline characteristics of patients who received pyrotinib after lapatinib failure.
| Characteristic | N (%) (n = 76) |
|---|---|
| Age | |
| Median (interquartile range) | 55 (46–60) |
| HR status | |
| HR positive | 35 (46.1) |
| HR negative | 33 (43.4) |
| Unknown | 8 (10.5) |
| Trastuzumab resistance | |
| Resistance | 23(30.3) |
| Refractoriness | 48(63.2) |
| Unknown | 5(6.6) |
| Visceral metastases | |
| Yes | 49 (64.5) |
| No | 27 (35.5) |
| Metastatic sites | |
| Lymph nodes | 16 (21.1) |
| Lung | 35 (46.1) |
| Liver | 17 (22.4) |
| Bone | 14 (18.4) |
| Brain | 14 (18.4) |
| Chest wall | 4 (5.3) |
| PFS of lapatinib therapy (months) | |
| <6.0 | 29 (38.2) |
| ⩾6.0 | 43 (56.6) |
| Unknown | 4 (5.3) |
| Lines of pyrotinib therapy | |
| 2 | 13 (17.1) |
| 3 | 23 (30.3) |
| ⩾4 | 40 (52.6) |
| Pyrotinib regimens | |
| Pyrotinib | 7 (9.2) |
| Pyrotinib + capecitabine | 38 (50.0) |
| Pyrotinib + vinorelbine | 12 (15.8) |
| Pyrotinib + trastuzumab | 6 (7.9) |
| Other | 13 (17.1) |
HR, hormone receptor; PFS, progression-free survival.